Focused On-demand Library for Gamma-aminobutyric acid receptor subunit alpha-3

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our top-notch dedicated system is used to design specialised libraries for receptors.

Fig. 1. The sreening workflow of Receptor.AI

This process includes extensive molecular simulations of the receptor in its native membrane environment, along with ensemble virtual screening that accounts for its conformational mobility. In the case of dimeric or oligomeric receptors, the entire functional complex is modelled, identifying potential binding pockets on and between the subunits to encompass all possible mechanisms of action.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

P34903

UPID:

GBRA3_HUMAN

Alternative names:

GABA(A) receptor subunit alpha-3

Alternative UPACC:

P34903; Q8TAF9

Background:

Gamma-aminobutyric acid receptor subunit alpha-3, also known as GABA(A) receptor subunit alpha-3, plays a pivotal role in the brain's inhibitory signaling by mediating the effects of GABA, the primary inhibitory neurotransmitter. This protein's function is crucial for maintaining the balance between neuronal excitation and inhibition, ensuring proper brain function.

Therapeutic significance:

The protein is linked to Epilepsy, X-linked 2, with or without impaired intellectual development and dysmorphic features, a neurological disorder characterized by epileptic seizures and varying degrees of intellectual disability. Understanding the role of Gamma-aminobutyric acid receptor subunit alpha-3 could open doors to potential therapeutic strategies for this condition.